RISA

Name: RISA
Brand: RISA

AI Native

Making Institutions Win!

Est 2024|Valuation $42M|Raised $14.6M

LinkedIn 20K|Website|Web traffic 2K|FTEs 48|HQ Palo Alto, CA

01Competitive Landscape

Narrative analysis

- RISA versus AKASA: AKASA has a broader RCM automation focus suitable for organizations standardizing across specialties. RISA emphasizes oncology-specific workflow depth and orchestration across multiple operational steps. - RISA versus Cohere Health: Cohere Health is positioned with payer-side decisioning and collaboration tooling, while RISA appears to be more provider-operations oriented, focusing on backlogs, filing authorizations, and reclaiming administrative time in oncology settings. - RISA versus Availity and clearinghouse ecosystems: Clearinghouses provide connectivity and transaction rails but typically do not provide the same level of workflow orchestration or configurable automation. Organizations weighing options may prefer established connectivity rails for reliability over newer orchestration approaches.

Adoption / market signals

RISA’s disclosed funding and investor mentions suggest strategic investor interest, but funding does not alone demonstrate broad market adoption.
Vendor statements indicate deployments at oncology practices; additional named customers beyond those referenced in press coverage are not clearly documented publicly.

	RISA (vendor product overview and feature pages)	AKASA (vendor product overview and feature pages)	Cohere Health (vendor product overview and feature pages)
Starting Price	Not public; press and vendor materials reference transformation and per-process fee components	Not public (enterprise)	Not public (enterprise)
Best For	Oncology providers seeking targeted automation and orchestration for prior authorization and related workflows	Providers seeking broader revenue cycle automation across specialties	Health plans and at-risk providers focused on utilization management and prior authorization decisioning
Key Strength	Oncology-focused workflow approach; vendor states emphasis on traceability and modular integration APIs	Broader RCM automation footprint and market presence	Payer-side positioning and tooling for collaborative UM and prior authorization processes
Key Weakness	Limited public third-party reviews and limited public security/compliance disclosures; new vendor risk	May lack deep oncology specialization relative to vertical providers	Provider sentiment can vary; product positioning focuses more on payer/provider collaboration

01Competitive Landscape

Narrative analysis

RISA versus AKASA: AKASA has a broader RCM automation focus suitable for organizations standardizing across specialties. RISA emphasizes oncology-specific workflow depth and orchestration across multiple operational steps.
RISA versus Cohere Health: Cohere Health is positioned with payer-side decisioning and collaboration tooling, while RISA appears to be more provider-operations oriented, focusing on backlogs, filing authorizations, and reclaiming administrative time in oncology settings.
RISA versus Availity and clearinghouse ecosystems: Clearinghouses provide connectivity and transaction rails but typically do not provide the same level of workflow orchestration or configurable automation. Organizations weighing options may prefer established connectivity rails for reliability over newer orchestration approaches.

Adoption / market signals

RISA’s disclosed funding and investor mentions suggest strategic investor interest, but funding does not alone demonstrate broad market adoption.
Vendor statements indicate deployments at oncology practices; additional named customers beyond those referenced in press coverage are not clearly documented publicly.

	RISA (vendor product overview and feature pages)	AKASA (vendor product overview and feature pages)	Cohere Health (vendor product overview and feature pages)
Starting Price	Not public; press and vendor materials reference transformation and per-process fee components	Not public (enterprise)	Not public (enterprise)
Best For	Oncology providers seeking targeted automation and orchestration for prior authorization and related workflows	Providers seeking broader revenue cycle automation across specialties	Health plans and at-risk providers focused on utilization management and prior authorization decisioning
Key Strength	Oncology-focused workflow approach; vendor states emphasis on traceability and modular integration APIs	Broader RCM automation footprint and market presence	Payer-side positioning and tooling for collaborative UM and prior authorization processes
Key Weakness	Limited public third-party reviews and limited public security/compliance disclosures; new vendor risk	May lack deep oncology specialization relative to vertical providers	Provider sentiment can vary; product positioning focuses more on payer/provider collaboration

RISA

01Competitive Landscape

Narrative analysis

Adoption / market signals

02Market Map

01Competitive Landscape

Narrative analysis

Adoption / market signals

02Market Map